Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

26 Mar 2009 15:47

RNS Number : 5628P
Amphion Innovations PLC
26 March 2009
 



Amphion Innovations plc

Directors Dealings

London and New York, 26 March 2009 - Amphion Innovations plc (LSE: AMP) ("Amphion" or the "Company"), the developer of medical and technology businesses, today announces that Chief Executive Officer, Richard Morgan and President and Chief Financial Officer, Robert Bertoldi, who are also both Board members, have received New Ordinary Shares in lieu of cash compensation. Richard Morgan received 632,209 Ordinary Shares, bringing his total holdings of the Company to 23,426,266 representing 17.85 per cent of the Company's enlarged issued ordinary share capital. Robert Bertoldi received  75,865 Ordinary Shares bringing his total holdings of the Company to 6,436,431 representing 4.90 per cent of the Company's enlarged issued Ordinary Share capital.

In addition to the 708,074 Ordinary Shares issued to Richard Morgan and Robert Bertoldi, 166,903 Ordinary Shares were also issued to six employees of the Company as part of their incentive compensation. Admission of the 874,977 new Ordinary Shares, ranking pari passu, is expected on 2 April 2009. Following this allotment the total issued share capital of the Company will increase to 131,253,834 Ordinary Shares.

In addition, the Company has to date granted options to employees and Directors under the Share Option Scheme in respect of 7,875,000 Ordinary Shares. The Company is now proposing to grant options in respect of a further 1,925,000 Ordinary Shares at an issue price of 10.75 pence per Ordinary Share to certain employees and Directors which shall be exercisable from 24 March 2010 under the terms of the Share Option Scheme. This will include options in respect of 500,000 Ordinary Shares granted to Richard Morgan and 350,000 Ordinary Shares granted to Robert Bertoldi

Richard Morgan also purchased 150,000 Ordinary Shares on 25 March 2009. Of this, 113,640 Ordinary shares in the Company were purchased at a price of 10 pence per share and 36,360 Ordinary Shares at 11 pence per share in the Company Accordingly, Richard Morgan is now beneficially interested in 23,576,266 Ordinary Shares representing 17.97% of the Company's issued Ordinary Share capital. 

For further information please contact

Amphion Innovations plcCharlie Morgan, Director of Communications +1 212 210 6224

Cardew Group Tim Robertson/ Jamie Milton/ Matthew Law +44 020 7930 0777

Charles Stanley Securities - Nominated AdviserMark Taylor / Freddy Crossley +44 20 7149 6000

About Amphion Innovations plc Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.

Amphion has significant shareholding in 10 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: www.amphionplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEQLFLKXBZBBE
Date   Source Headline
22nd Dec 20177:01 amRNSComment on Polarean Fund Raise
22nd Dec 20177:00 amRNSRestructure of Loan and Additional Drawdown
5th Dec 20177:00 amRNSIssue of Shares
23rd Nov 20177:00 amRNSFurther Update on Polarean Imaging Limited
10th Nov 20177:00 amRNSUpdate on Polarean Imaging Limited
2nd Nov 20177:00 amRNSOrder Dismissing DataTern Case
11th Oct 20177:00 amRNSRelated Party Transaction
5th Oct 20177:00 amRNSPartner Company releases positive clinical results
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
25th Sep 20177:00 amRNSSale of Partner Company Shares
30th Aug 20177:00 amRNSSale of partner company shares
30th Aug 20177:00 amRNSHolding(s) in Company
1st Aug 20175:19 pmRNSAGM Statement
28th Jun 20177:00 amRNSFinal Results
31st May 20177:00 amRNSPartner Company m2m Imaging merger update
22nd May 20174:36 pmRNSAdditional Draw Down on Loan Facility
7th Feb 20177:00 amRNSAdditional Draw Down on Loan Facility
1st Feb 20175:18 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
16th Dec 20163:07 pmRNSDirector/PDMR Shareholding
9th Dec 20163:50 pmRNSDirector/PDMR Shareholding
24th Nov 20162:15 pmRNSHolding(s) in Company
8th Sep 20167:00 amRNSRe-negotiated terms of Motif CPN
7th Sep 20167:00 amRNSInterim Results for the six months to 30 June 2016
22nd Aug 20163:58 pmRNSAdditional Draw Down on Loan Facility
3rd Aug 20164:13 pmRNSHolding(s) in Company
29th Jul 20167:00 amRNSResults of AGM and Directorate Change
18th Jul 20164:33 pmRNSTransfer of Shares
13th Jul 20167:01 amRNSNotice of Intention to List on NASDAQ by Motif Bio
13th Jul 20167:00 amRNSAdditional Draw Down on Loan Facility
23rd Jun 20167:00 amRNSFinal Results
29th Apr 20164:02 pmRNSAdditional Terms on Loan Facility
28th Apr 20167:00 amRNSAdditional Draw Down on Loan Facility
7th Apr 20167:00 amRNSAmphion settles contested arbitration ruling
3rd Mar 20167:00 amRNSConvertible Promissory Note Extended
7th Jan 20167:00 amRNSDirectors' Dealings
5th Jan 20167:00 amRNSConvertible Promissory Note Terms Extended
26th Nov 20157:00 amRNSAdditional Draw on Loan Facility
5th Nov 20157:00 amRNSPartner Company m2m Imaging Corp. to merge
30th Oct 20154:20 pmRNSDeath of a Director - Replacement
30th Oct 20153:50 pmRNSDeath of a Director
17th Sep 20157:00 amRNSAmphion to present in London
16th Sep 20157:00 amRNSDirectors' Dealings
10th Sep 20157:00 amRNSDataTern Receives Favourable Ruling
3rd Sep 20157:00 amRNSInterim Results
28th Aug 20159:08 amRNSHolding(s) in Company
7th Aug 20155:15 pmRNSResult of AGM
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.